MDT Stock Recent News
MDT LATEST HEADLINES
Buying battle-tested dividend aristocrats can be a winning strategy for those seeking durable retirement income. What's even better is if they also carry strong balance sheets and are attractively valued. In this article, I highlight 2 such picks, which, on a combined basis, offer immediate diversification and potential for market-beating total returns.
Medtronic's strong liquidity position should allow it to meet its near-term debt obligations.
For not just years but decades, Medtronic (MDT 0.04%) has proven to be a reliable dividend growth stock to own. The medical device maker has been increasing its payout regularly, and with a yield of more than 3%, it pays more than twice what the S&P 500 averages (1.3%).
Shares of Medtronic have lagged the S&P 500 index in the months since my previous article. The company's revenue and non-GAAP EPS grew during its fiscal Q2. Medtronic boasts an A credit rating from S&P on a stable outlook.
Medtronic offers value and income potential with a 3.5% dividend yield, strong fundamentals, and 47 years of consecutive dividend increases. Despite recent share price underperformance, MDT shows solid revenue and EPS growth driven by innovation in high-growth healthcare segments. MDT's forward P/E ratio of 14.9 is well below its historical average, indicating potential for valuation upside.
In the closing of the recent trading day, Medtronic (MDT) stood at $83.92, denoting a -1.27% change from the preceding trading day.
Disney's (DIS) annual shareholder meeting, which will decide Disney's board membership, will take place on April 3. The vote has attracted media attention as activist Nelson Peltz has questioned Disney's current leadership and seeks to embed his views in the company.
Stock markets are reaching new highs and exuberance is in the air. For value investors, this might seem like a perplexing time.
Medtronic MDT (NYSE: MDT) recently reported its Q3 fiscal 2024 results (fiscal ends in April), with revenues and earnings beating the street estimates. The company reported revenue of $8.1 billion and adjusted earnings of $1.30 per share compared to the consensus estimates of $7.9 billion and $1.26, respectively.
Medtronic's (MDT) third-quarter organic growth reflects broad strength across businesses and geographies.